Sadly I have to fully agree with the sentiment expressed in your post. When I joined this forum over two years ago I believe one of my first posts stated something along the lines that Resverlogix was an investment in which it remained to be seen whether amazing science could prevail through mediocre business management. Sadly I think this is still a valid question. When management started including the milestone checklist I was somewhat hopeful that they were going to step up their effort in communication and accountability. However since they have stumbled on the way to meeting some of their goals management has dispensed with the milestone list altogether instead of being accountable. 

In particular I find the failures in two things on the list extremely frustrating. 1) We have been hearing for quite some time about the exciting, clinic ready new compounds but have yet to see a shred of evidence of this.  2) IMO it borders on disgraceful that in September it will be 2 years since Dr KZ expressed his excitement over Apabetalones' potential too treat CKD and since then we have had one small, short trial which produced 'groundbreaking' results and yet a small ph 2a is still listed as not yet recruiting. Is it poor organization, lack of funding or a combination of both which is impeding progress?  In any event these and the other failings from the milestone checklist are failures in business management.  

IMO this is a huge reason for lack of new retail investment in Resverlogix. Management squandering opportunity to expand the companys' opportunity base has left RVX to remain a higher risk one trick pony in the markets eyes.